Introducing Lonza’s AAV suspension transient transfection platform to de-risk your path to clinic
s
Feb
24
2022
On demand

Introducing Lonza’s AAV suspension transient transfection platform to de-risk your path to clinic

Thursday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Sponsor
Introducing Lonza’s AAV suspension transient transfection platform to de-risk your path to clinic

Adeno associated viral vector (AAV) is the delivery vehicle of choice for potentially curative in vivo gene therapy. Following a couple of landmark approvals, this field has experienced accelerated pipeline growth and investor interest in the past five years. Currently AAV therapies are predominantly targeting rare genetic disorders for which the patient population is often limited. As a result, drug developers feel immense pressure to be first to market to commercialize their therapies. 

In this Webinar, Lonza CGT will focus on a robust, streamlined platform process for fast production of AAV using Lonza’s clonal suspension HEK293 cell line, proprietary plasmids to ensure high productivity and in process analytics enabling enhanced full to empty capsid ratio. We will further discuss Lonza’s approach for building reliable, de-risked path to clinic to avoid unforeseen costs and compliance-related delays.

  • Speed to clinic with a de-risked, robust, scalable platform process for AAV production
  • High AAV productivity and yield with Lonza’s proprietary plasmids (Rep/cap + pHelper) and clonal HEK293 cell line
  • Full/empty analytics enabling USP and DSP optimization at early stages/small scale
  • Pre-qualified platform assays


Suparna Sanyal
Suparna Sanyal
CD at Lonza
Suparna Sanyal is an Innovation and Commercialization Manager at Lonza Cell and Gene Technologies where she works with their global business, R&D and operations teams to enable prioritization, strategic development and commercialization of their innovation portfolio. Suparna’s background is in Neuroscience and she earned her PhD from the University of Toronto in Neuropharmacology. She has over 15 years of broad pharmaceutical and CDMO experience driving innovation, drug discovery, product and service development for CNS, oncology and cell and gene therapy.